comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 15:21:11 - browse：2269

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Rock icon Freddie Mercury pre

WSS

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Roche to buy Carmot Therapeutics, developer of obesity drugs

Slain Parkland victim's father speaks out following reenactment

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Parkland mass shooting to be reenacted for lawsuit

entertainment

comprehensive

knowledge

Alkermes shareholders re

Pharma needs to include young adults in clinical research

As demand for Covid shots wanes, Moderna seeks its next success

Medical mystery: When an infection after surgery isn’t what it seems

New air purifier tech could be key to improving indoor air quality

California Joshua trees severely burned in massive wildfire

Anesthesiologist group: stop taking Ozempic before surgery

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Drug repurposing or repositioning? The language matters

New company forms to vet health AI models, root out weaknesses

explore

What causes an itch? Researchers may have solved the mystery

Supreme Court wrestles with OxyContin maker's bankruptcy deal

What PEPFAR has meant on the ground in Ukraine

The woman behind the Dana Farber

New company forms to vet health AI models, root out weaknesses

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Wikipedia

hotspot

hotspot

focus